PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 463-470

  Benjamin, Arko Boham ^a,b   Zhou, Xin ^a   Isaac, Okai ^a,c   Zhao, Haoqi ^a   Song, Yang ^a   Chi, Xinming ^a   Sun, Bing ^a   Hao, Lihong ^a   Zhang, Liyuan ^a   Liu, Lu ^a   Guan, Hongwei ^a   Shao, Shujuan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF GHANA   (Ghana)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

Cell proliferation; Lung carcinoma; P21; PRP19

Indexed keywords

CISPLATIN; CYCLIN D1; MESSENGER RNA; PROTEIN; PROTEIN P21; PROTEIN P53; PROTEIN PRP19; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PRPF19 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA REPAIR ENZYMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; TRANSFECTION; UP-REGULATION;

EID: 84901631390     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.006     Document Type: Article

References (48)

1. Danaei G., Hoorn H.V., Lopez D.A., Murray J.L.C., Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005, 366(9499):1784-1793.
2. Lobo N.A., Shimono Y., Qian D., Michael F., Clarke M.F. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-699.
3. Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell 2011, 144(4):646-674.
4. Sahai E. Mechanism of cancer cell invasion. Curr Opin Genet 2005, 15:87-96.
5. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1060.
6. Borczuk A.C., Gorenstein L., Walker K.L., Assaad A.A., Wang L., Powell C.A. Non-small cell lung cancer molecular signatures recapitulate lung development pathways. Am J Pathol 2003, 163:1949-1960.
7. Spiro S.G., Silvestri G.A. One hundred years of lung cancer. AJRCCM 2005, 172:523-529.
8. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
9. Zöchbauer-Müller S., Gazdar A.F., Minna J.D. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002, 64:681-708.
10. Zu Y.F., Wang X.C., Chen Y., Wang J.Y., Xin L., Li C.W., et al. Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer. Oncol Rep 2012, 28:1544-1550.
11. Gibbs A.R., Thunnissen F.B.J.M. Histological typing of lung and pleural tumours: third edition. J Clin Pathol 2001, 54:498-499.
12. Swensen S.J., Jett J.R., Hartman T.E., Midthun D.E., Sloan J.A., Sykes A.M., et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003, 226:756-761.
13. Cheng S.C., Tarn W.Y., Tsao T.Y., Abelson J. PRP19: a novel spliceosomal component. Mol Cell Biol 1993, 13(3):1876-1882.
14. Gotzmann J., Gerner C., Meissner M., Holzmann K., Grimm R., Mikulits W., et al. hMNP: a novel human common nuclear matrix protein combining structural and regulatory functions. Exp Cell Res 2000, 261:116-179.
15. Mahajan K.N., Mitchell B.S. Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transerase. PNAS 2003, 100(19):10746-10751.
16. Voglauer R., Chang M.W.F., Dampier B., Weiser M., Baumann K., Sterovsky T., et al. SNEV overexpression extends the life span of human endothelial cells. Exp Cell Res 2006, 312:746-759.
17. Fortschegger K., Wagner B., Voglauer R., Katinger H., Sibilia M., Grillari J. Early embryonic lethality of mice lacking the essential protein SNEV. Mol Cell Biol 2007, 27(8):3123-3130.
18. Vander Kooi C.W., Ren L., Xu P., Ohi M.D., Gould K.L., Chazin W.J. The Prp19 WD40 domain contains a conserved protein interaction region essential for its function. Structure 2010, 18:584-593.
19. Tsai W.T., Chow Y.T., Chen H.R., Huang K.T., Hong R.I., Jan S.P., et al. Cef1p is a component of the Prp19p-associated complex and essential for pre-mRNA splicing. J Biol Chem 1999, 274:9455-9462.
20. Makarova O.V., Makarov E.M., Urlaub H., Will C.L., Gentzel M., Wilm M., et al. A subset of human 35S U5 proteins, including Prp19, function prior to catalytic step 1 of splicing. EMBO J 2004, 23:2381-2390.
21. Tarn W.Y., Hsu C.H., Huang K.T., Chen H.R., Hao H.Y., Lee K.R., et al. Functional association of essential splicing factor(s) with Prp19 in a protein complex. EMBO J 1994, 13:2421-2430.
22. Grote M., Wolf E., Will C.L., Lemm I., Agafonov D.E., Schomburg A., et al. Molecular architecture of the human Prp19/CDC5L complex. Mol Cell Biol 2010, 30(9):2105-2119.
23. Ohi M.D., Vander Kooi C.W., Rosenberg J.A., Ren L., Hirsch J.P., Chazin W.J., et al. Structural and functional analysis of essential pre-mRNA splicing factor Prp19p. Mol Cell Biol 2005, 25:451-460.
24. Urano Y., Iiduka M., Sugiyama A., Akiyama A., Uzawa K., Matsumoto G., et al. Involvement of the mouse Prp19 gene in neuronal/astroglial cell fate decision. J Biol Chem 2006, 281(11):7498-7514.
25. Xiaoyan L., Legerski R.J. The Prp19/Pso4 core complex undergoes uniquitination and structural alterations in response to DNA damage. Biochem Biophys Res Commun 2007, 354(4):968-974.
26. Song E.J., Werner S.L., Neunauer J., Stegmeier F., Aspden J., Rio D., et al. The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible uniquitination at the spliceosome. Genes Dev 2010, 24:1434-1447.
27. Sittinan C., Seizl M., Sträßer K. The Prp19 complex is a novel transcription elongation factor required for TREX occupancy at transcribed genes. Genes Dev 2011, 25:1147-1158.
28. hPrp19/hPso4 is involved in extending cellular life span and suppression of apoptosis. Aging 2012, 4(4):290-304.
29. Kaufmann D., Leistner W., Kruse P., Kenner O., Hoffmeyer S., Hein C., et al. Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 21. Cancer Res 2002, 62:1503-1509.
30. Confalonieri S., Quarto M., Goisis G., Nuciforo P., Donzelli M., Jodice G., et al. Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene 2009, 28:2959-2968.
31. Gautreau A., Manent J., Fievet B., Louvard D., Giovannini M., Arpin M. Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 2002, 277:3510-3515.
32. Sun Y. E3 Ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006, 8:645-654.
33. Jing G.J., Xu D.H., Shi S.L., Li Q.F., Wang S.Y., Wu F.Y., et al. Aberrant expression of nuclear matrix proteins during HMBA-induced differentiation of gastric cancer cells. World J Gastroenterol 2010, 16(17):2176-2182.
34. Okai I., Wang L., Gong L., Arko-Boham B., Hao L., Zhou X., et al. Overexpression of JAKMIP1 associates with Wnt/beta-catenin pathway activation and promotes cancer cell proliferation. Biomed Pharmacother 2013, 67:228-234.
35. Seki Y., Suico M.A., Uto A., Hisatsune A., Shuto T., Isohama Y., et al. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res 2002, 62:6579-6586.
36. Baldi A., De Luca A., Esposito V., Campioni M., Spugnini E.P., Cito G. Tumour suppressors and cell cycle proteins in lung cancer. Pathol Res Intl 2011, 10.4061/2011/605042.
37. Gupta S., Ahmad N., Nieminen A.L., Mukhtar H. Growth inhibition, cell cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000, 164(1):82-90.
38. Fernàndez V., Hartmann E., Ott G., Campo E., Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005, 23:6364-6369.
39. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
40. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Scott W., Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999, 13:2670-2677.
41. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., et al. p53-independent functions of the p19ARFtumor suppressor. Genes Dev 2000, 14:2358-2365.
42. El-Diery W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
43. Wu R.C., Schönthal A.H. Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem 1997, 272(46):29091-29098.
44. Weber H.O., Samuel T., Rauch P., Funk J.O. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002, 21:3207-3212.
45. Stordal B., Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59(11):696-699.
46. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., et al. p53-Dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995, 9:935-944.
47. Bartek J., Lukas J. Mammalian G1 and S phase checkpoints in response to DNA damage. Curr Opin Cell Biol 2001, 13:738-747.
48. Zhang M.F., Zhang Z.Y., Fu J., Yang Y.F., Yun J.P. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 2009, 7(110). 10.1186/1479-5876-7-110.